Armistice Capital LLC Boosts Holdings in Kura Oncology, Inc. $KURA

Armistice Capital LLC boosted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 5.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,936,000 shares of the company’s stock after acquiring an additional 264,000 shares during the period. Kura Oncology accounts for 0.6% of Armistice Capital LLC’s holdings, making the stock its 22nd biggest position. Armistice Capital LLC owned 5.67% of Kura Oncology worth $51,285,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KURA. State Street Corp increased its stake in Kura Oncology by 47.5% during the 4th quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after buying an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after buying an additional 965,256 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its holdings in Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares in the last quarter.

Kura Oncology Stock Up 1.8%

Shares of NASDAQ:KURA opened at $9.57 on Thursday. The company has a market capitalization of $849.53 million, a PE ratio of -2.86 and a beta of 0.36. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. Kura Oncology, Inc. has a twelve month low of $5.45 and a twelve month high of $12.49. The firm has a 50 day simple moving average of $9.37 and a 200-day simple moving average of $9.26.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.05. The business had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, equities analysts predict that Kura Oncology, Inc. will post -3.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on KURA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Wedbush cut their price objective on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Citizens Jmp reiterated a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a research report on Monday. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, June 4th. Finally, Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.46.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.